食道癌治療薬の市場規模・シェア・展望・機会 (2022年～2028年)：治療タイプ (化学療法・標的薬物療法・免疫療法)・適応症・流通チャネル・地域別

世界の食道癌の有病率の増加が食道癌治療薬市場の成長を後押しすると予想されています。

当レポートでは、世界の食道癌治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、技術動向、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・法規制・動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 市場動向
• 主な展開
• 規制状況
• 製品回収
• 疫学分析
• 技術概要
• PEST分析
• ポーターのファイブフォース分析

第4章 世界の食道癌治療薬市場：治療タイプ別

• 化学療法
• 標的薬物療法
• 免疫療法

第5章 世界の食道癌治療薬市場：適応症別

• 腺癌
• 消化管間質腫瘍
• カルチノイド腫瘍
• 扁平上皮癌
• その他

第6章 世界の食道癌治療薬市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 世界の食道癌治療薬市場：地域別

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• アフリカ
• 中東

第8章 競合情勢

• 企業プロファイル
  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Johnson &Johnson
  • Gilead Sciences
  • Genentech Inc.
  • Sanofi-Aventis
  • Merck &Co.
• アナリストの見解

第9章 セクション

Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.

Market Dynamics

Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2021, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2021, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2021, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.

However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.

Key features of the study:

• This report provides in-depth analysis of the esophageal cancer drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global esophageal cancer drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global esophageal cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

• Global Esophageal Cancer Drugs Market, By Therapy Type:
• Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine and Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with Capecitabine
• Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
• Immunotherapy
  • Pembrolizumab
• Global Esophageal Cancer Drugs Market, By Disease Indication:
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Squamous Cell Carcinoma
• Others
• Global Esophageal Cancer Drugs Market, By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Global Esophageal Cancer Drugs Market, By Region:
• North America
  • By Country:
• U.S.
• Canada
  • By Therapy Type:
• Chemotherapy
• Docetaxel
• Irinotecan
• Trifluridine and Tipiracil
• Carboplatin and Paclitaxel
• Cisplatin and 5-fluorouracil
• Cisplatin with Capecitabine
• Targeted Drug Therapy
• Trastuzumab
• Ramucirumab
• Immunotherapy
• Pembrolizumab
  • By Disease Indication:
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Squamous Cell Carcinoma
• Others
  • By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Europe
  • By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
  • By Therapy Type:
• Chemotherapy
• Docetaxel
• Irinotecan
• Trifluridine and Tipiracil
• Carboplatin and Paclitaxel
• Cisplatin and 5-fluorouracil
• Cisplatin with Capecitabine
• Targeted Drug Therapy
• Trastuzumab
• Ramucirumab
• Immunotherapy
• Pembrolizumab
  • By Disease Indication:
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Squamous Cell Carcinoma
• Others
  • By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Asia Pacific
  • By Country:
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
  • By Therapy Type:
• Chemotherapy
• Docetaxel
• Irinotecan
• Trifluridine and Tipiracil
• Carboplatin and Paclitaxel
• Cisplatin and 5-fluorouracil
• Cisplatin with Capecitabine
• Targeted Drug Therapy
• Trastuzumab
• Ramucirumab
• Immunotherapy
• Pembrolizumab
  • By Disease Indication:
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Squamous Cell Carcinoma
• Others
  • By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Latin America
  • By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
  • By Therapy Type:
• Chemotherapy
• Docetaxel
• Irinotecan
• Trifluridine and Tipiracil
• Carboplatin and Paclitaxel
• Cisplatin and 5-fluorouracil
• Cisplatin with Capecitabine
• Targeted Drug Therapy
• Trastuzumab
• Ramucirumab
• Immunotherapy
• Pembrolizumab
  • By Disease Indication:
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Squamous Cell Carcinoma
• Others
  • By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Middle East
  • By Country:
• GCC
• Israel
• Rest of Middle East
  • By Therapy Type:
• Chemotherapy
• Docetaxel
• Irinotecan
• Trifluridine and Tipiracil
• Carboplatin and Paclitaxel
• Cisplatin and 5-fluorouracil
• Cisplatin with Capecitabine
• Targeted Drug Therapy
• Trastuzumab
• Ramucirumab
• Immunotherapy
• Pembrolizumab
  • By Disease Indication:
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Squamous Cell Carcinoma
• Others
  • By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Africa
  • By Country/Region:
• South Africa
• Central Africa
• North Africa
  • By Therapy Type:
• Chemotherapy
• Docetaxel
• Irinotecan
• Trifluridine and Tipiracil
• Carboplatin and Paclitaxel
• Cisplatin and 5-fluorouracil
• Cisplatin with Capecitabine
• Targeted Drug Therapy
• Trastuzumab
• Ramucirumab
• Immunotherapy
• Pembrolizumab
  • By Disease Indication:
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Squamous Cell Carcinoma
• Others
  • By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Company Profiles
• Amgen Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• GlaxoSmithKline Plc.
• Novartis AG
• Johnson & Johnson
• Gilead Sciences
• Genentech Inc.
• Sanofi-Aventis
• Merck & Co.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Therapy Type
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Landscape
• Product Recall
• Epidemiology Analysis
• Technology Overview
• PEST Analysis
• Porter's Five Forces model

4. Global Esophageal Cancer Drugs Market, By Therapy Type, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028(%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Docetaxel
  • Irinotecan
  • Trifluridine and tipiracil
  • Carboplatin and paclitaxel
  • Cisplatin and 5-fluorouracil
  • Cisplatin with capecitabine
• Targeted Drug Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Trastuzumab
  • Ramucirumab
• Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Pembrolizumab

5. Global Esophageal Cancer Drugs Market, By Disease Indication, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028(%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Adenocarcinomas
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Gastrointestinal Stromal Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Carcinoid Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Squamous Cell Carcinoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Esophageal Cancer Drugs Market, By Distribution Channel 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028(%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Esophageal Cancer Drugs Market, By Region, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028(%)
  • Y-o-Y Growth Analysis, By Region, 2017 - 2028
  • Regional Trends
• North America
  • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • U.S.
  • Canada
• Europe
  • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Africa
  • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa
• Middle East
  • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East

8. Competitive Landscape

• Company Profiles
  • Amgen Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Eli Lilly and Company
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • F. Hoffmann-La Roche
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Bristol-Myers Squibb Company
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Boehringer Ingelheim GmbH
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Bristol-Myers Squibb
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • GlaxoSmithKline Plc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Novartis AG
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Johnson & Johnson
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Gilead Sciences
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Genentech Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Sanofi-Aventis
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Merck & Co.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About us and Sales Contact